Aspergillosis due to Voriconazole Highly Resistant Aspergillus fumigatus and Recovery of Genetically Related Resistant Isolates From Domiciles
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Azole resistance is an emerging problem in Aspergillus fumigatus and complicates the management of patients with Aspergillus-related diseases. Selection of azole resistance may occur through exposure to azole fungicides in the environment. In the Netherlands a surveillance network was used to investigate the epidemiology of resistance selection in A. fumigatus. METHODS: Clinical A. fumigatus isolates were screened for azole resistance in 8 university hospitals using azole agar dilution plates. Patient information was collected using an online questionnaire and azole-resistant A. fumigatus isolates were analyzed using gene sequencing, susceptibility testing, and genotyping. Air sampling was performed to investigate the presence of resistant isolates in hospitals and domiciles. RESULTS: Between December 2009 and January 2011, 1315 A. fumigatus isolates from 921 patients were screened. A new cyp51A-mediated resistance mechanism (TR46/Y121F/T289A) was observed in 21 azole-resistant isolates from 15 patients in 6 hospitals. TR46/Y121F/T289A isolates were highly resistant to voriconazole (minimum inhibitory concentration ≥16 mg/L). Eight patients presented with invasive aspergillosis due to TR46/Y121F/T289A, and treatment failed in all 5 patients receiving primary therapy with voriconazole. TR46/Y121F/T289A Aspergillus fumigatus was recovered from 6 of 10 sampled environmental sites. CONCLUSIONS: We describe the emergence and geographical migration of a voriconazole highly resistant A. fumigatus that was associated with voriconazole treatment failure in patients with invasive aspergillosis. Recovery of TR46/Y121F/T289A from the environment suggests an environmental route of resistance selection. Exposure of A. fumigatus to azole fungicides may facilitate the emergence of new resistance mechanisms over time, thereby compromising the use of azoles in the management of Aspergillus-related diseases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The highest rates of both azole and echinocandin resistance are observed in Candida glabrata and Candida tropicalis30 (Table 1).”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [30]
Citations
Cites
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., Kauffman, C. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/588660 · Cited by 4,917
Walsh, T. J., Anaissie, E. J., Denning, D. W., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Segal, B. H., Steinbach, W. J., Stevens, D. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/525258 · Cited by 2,706
Howard, S. J., Cerar, D., Anderson, M. J., Albarrag, A., Fisher, M. C., Pasqualotto, A. C., Laverdiere, M., Arendrup, M. C., Perlin, D. S., & Denning, D. W. (2009) · Emerging Infectious Diseases · doi:10.3201/eid1507.090043 · Cited by 750
Emergence of Azole Resistance in Aspergillus fumigatus and Spread of a Single Resistance Mechanism
Snelders, E., van der Lee, H. A. L., Kuijpers, J., Rijs, A. J. M. M., Varga, J., Samson, R. A., Mellado, E., Donders, A. R. T., Melchers, W. J. G., & Verweij, P. E. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050219 · Cited by 727
Self-citationAzole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use?
Verweij, P. E., Snelders, E., Kema, G. H., Mellado, E., & Melchers, W. J. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70265-8 · Cited by 604
Self-citationMellado, E., Garcia-Effron, G., Alcázar-Fuoli, L., Melchers, W. J. G., Verweij, P. E., Cuenca-Estrella, M., & Rodríguez-Tudela, J. L. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01092-06 · Cited by 490
Self-citationClinical Implications of Azole Resistance in Aspergillus fumigatus, the Netherlands, 2007–2009
van der Linden, J. W. M., Snelders, E., Kampinga, G. A., Rijnders, B. J. A., Mattsson, E., Debets-Ossenkopp, Y. J., Kuijper, E. J., Van Tiel, F. H., Melchers, W. J. G., & Verweij, P. E. (2011) · Emerging Infectious Diseases · doi:10.3201/eid1710.110226 · Cited by 446
Self-citationTriazole Fungicides Can Induce Cross-Resistance to Medical Triazoles in Aspergillus fumigatus
Snelders, E., Camps, S. M. T., Karawajczyk, A., Schaftenaar, G., Kema, G. H. J., van der Lee, H. A., Klaassen, C. H., Melchers, W. J. G., & Verweij, P. E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031801 · Cited by 427
Self-citationPossible Environmental Origin of Resistance of Aspergillus fumigatus to Medical Triazoles
Snelders, E., Huis in 't Veld, R. A. G., Rijs, A. J. M. M., Kema, G. H. J., Melchers, W. J. G., & Verweij, P. E. (2009) · Applied and Environmental Microbiology · doi:10.1128/aem.00231-09 · Cited by 423
Self-citationMultiple-Triazole–Resistant Aspergillosis
Verweij, P. E., Mellado, E., & Melchers, W. J. G. (2007) · New England Journal of Medicine · doi:10.1056/nejmc061720 · Cited by 380
Self-citation
Research works printed but not linked: 1
- Van der Linden, 2009, Azole containing agar plates as a screening tool for azole resistance of Aspergillus fumigatus, Mycoses, 52, S1
Cited by
Items 101–200 of 349
Gamaletsou, M. N., Walsh, T. J., & Sipsas, N. V. (2018) · Turkish Journal of Hematology · doi:10.4274/tjh.2018.0007 · Cited by 64
“Several studies have shown that triazole resistance is associated with treatment failure, especially among patients with HMs [24,28,29,36,39].”
BackgroundBuil, J. B., Hagen, F., Chowdhary, A., Verweij, P. E., & Meis, J. F. G. M. (2018) · Journal of Fungi · doi:10.3390/jof4030103 · Cited by 61
Self-citationAzole resistance surveillance in Aspergillus fumigatus: beneficial or biased?
Verweij, P. E., Lestrade, P. P. A., Melchers, W. J. G., & Meis, J. F. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw259 · Cited by 59
Self-citationGarvey, M., Meade, E., & Rowan, N. J. (2022) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2022.158284 · Cited by 64
“Hollandfor example,whereazolesareusedabundantlyintulipfarming has one of the highest rates of azole resistance strains of A. fumigatus (van der Linden et al., 2013).”
BackgroundNeoh, C. F., Chen, S. C. ‐., Lanternier, F., Tio, S. Y., Halliday, C. L., Kidd, S. E., Kong, D. C. M., Meyer, W., Hoenigl, M., & Slavin, M. A. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00004-23 · Cited by 58
Buil, J. B., van der Lee, H. A. L., Rijs, A. J. M. M., Zoll, J., Hovestadt, J. A. M. F., Melchers, W. J. G., & Verweij, P. E. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01250-17 · Cited by 57
“For all isolates, the full cyp51A gene and promoter region had been sequenced (4).”
BackgroundSelf-citationThe Emerging Threat of Antifungal Resistance in Transplant Infectious Diseases
Schwartz, I. S., & Patterson, T. F. (2018) · Current Infectious Disease Reports · doi:10.1007/s11908-018-0608-y · Cited by 57
Lescar, J., Meyer, I., Akshita, K., Srinivasaraghavan, K., Verma, C., Palous, M., Mazier, D., Datry, A., & Fekkar, A. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku316 · Cited by 54
Liu, M., Zeng, R., Zhang, L., Li, D., Lv, G., Shen, Y., Zheng, H., Zhang, Q., Zhao, J., Zheng, N., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00003-15 · Cited by 52
Buil, J. B., Hare, R. K., Zwaan, B. J., Arendrup, M. C., Melchers, W. J. G., & Verweij, P. E. (2019) · PLoS Pathogens · doi:10.1371/journal.ppat.1007858 · Cited by 56
Self-citationEditorial Commentary: Voriconazole Resistance in Aspergillus fumigatus: Should We Be Concerned?
Denning, D. W., & Bowyer, P. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit321 · Cited by 58
“%) contained the new resistant mutation TR46/Y121F/T289A [2].”
InfluentialPerlin, D. S., & Wiederhold, N. P. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix121 · Cited by 49
Spieß, B., Postina, P., Reinwald, M., Cornely, O. A., Hamprecht, A. G., Hoenigl, M., Lass‐Flörl, C., Rath, P., Steinmann, J., Miethke, T., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103113 · Cited by 51
“8%) [4,8] and 1/1 [100%] hematological patients [11] with multi-azole resistant IA died under azole therapy, thus underlining the necessity of using non-culture based assays for both the detection of Aspergillus spp.”
BackgroundInfluentialMulti-azole resistant Aspergillus fumigatus harboring Cyp51A TR46/Y121F/T289A isolated in Japan
Hagiwara, D., Takahashi, H., Fujimoto, M., Sugahara, M., Misawa, Y., Gonoi, T., Itoyama, S., Watanabe, A., & Kamei, K. (2016) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2016.01.015 · Cited by 51
Pharmacokinetics and Pharmacodynamics of Antifungals in Children and their Clinical Implications
Stockmann, C. R., Constance, J. E., Roberts, J. K., Olson, J. A., Doby, E. H., Ampofo, K., Stiers, J., Spigarelli, M. G., & Sherwin, C. M. T. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0139-0 · Cited by 57
“Perhaps most concerning, the authors recovered these highly resistant strains from the air of the hospital paediatric ward as well as the patients’ homes and backyards [215].”
BackgroundAzole Resistance in Aspergillus fumigatus in Patients with Cystic Fibrosis: A Matter of Concern?
Hamprecht, A. G., Morio, F., Bader, O., Pape, P. L., Steinmann, J., & Dannaoui, É. (2017) · Mycopathologia · doi:10.1007/s11046-017-0162-4 · Cited by 49
“TR46/Y121F/T289A has first been described in Belgium and the Netherlands [51, 53] and later in other European countries [46, 47, 53], but is probably distributed worldwide.”
BackgroundAzole-resistant Aspergillus fumigatus in the Italian environment
Prigitano, A., Esposto, M. C., Romanò, L., Auxilia, F., & Tortorano, A. M. (2018) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2018.10.017 · Cited by 52
N -Myristoyltransferase Is a Cell Wall Target in Aspergillus fumigatus
Fang, W., Robinson, D. A., Raimi, O. G., Blair, D. E., Harrison, J. R., Lockhart, D. E. A., Torrie, L. S., Ruda, G. F., Wyatt, P. G., Gilbert, I. H., et al. (2015) · ACS Chemical Biology · doi:10.1021/cb5008647 · Cited by 52
Emerging Issues in Antifungal Resistance
Perfect, J. R., & Ghannoum, M. (2020) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2020.05.003 · Cited by 47
Abdolrasouli, A., Scourfield, A., Rhodes, J. L., Shah, A., Elborn, J. S., Fisher, M. C., Schelenz, S., & Armstrong-James, D. P. H. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.08.004 · Cited by 49
Tebuconazole induces triazole-resistance in Aspergillus fumigatus in liquid medium and soil
Cui, N., He, Y., Yao, S., Zhang, H., Ren, J., Fang, H., & Yu, Y. (2018) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2018.08.247 · Cited by 45
Rocchi, S., Daguindau, E., Grenouillet, F., Deconinck, E., Bellanger, A.-P., Garcia-Hermoso, D., Bretagne, S., Reboux, G., & Millon, L. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.03182-13 · Cited by 38
“The other recently described fungicide-driven route of the resistance mechanism TR46 Y121F/T289A, also found in hematology patients with IA, can easily spread further (13).”
BackgroundVoriconazole-Susceptible and Voriconazole-Resistant Aspergillus fumigatus Coinfection
Kolwijck, E., van der Hoeven, H., de Sévaux, R. G. L., ten Oever, J., Rijstenberg, L. L., van der Lee, H. A. L., Zoll, J., Melchers, W. J. G., & Verweij, P. E. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201510-2104le · Cited by 41
Self-citationChoukri, F., Botterel, F., Sitterlé, E., Bassinet, L., Foulet, F., Guillot, J., Costa, J. M., Fauchet, N., & Dannaoui, E. (2015) · Medical Mycology · doi:10.1093/mmy/myv029 · Cited by 40
“In vitro susceptibility to azoles was screened by subculturing each isolate on RPMI agar plates supplemented with itraconazole (Sigma-Aldrich, Saint-Quentin Fallavier France) at 4 mg/l and voriconazole (Sigma-Aldrich) at 1 mg/l as previously described [11].”
MethodMontesinos, I., Argudín, M. A., Hites, M., Ahajjam, F., Dodémont, M., Dagyaran, C., Bakkali, M., Etienne, I., Jacobs, F., Knoop, C., et al. (2017) · Journal of Clinical Microbiology · doi:10.1128/jcm.00520-17 · Cited by 42
“selection (mainly TR34/L98H and TR46/Y121F/T289A) caused by the use of fungicides in agriculture, as confirmed by molecular typing (12, 15).”
BackgroundDauchy, C., Bautin, N., Nseir, S., Reboux, G., Wintjens, R., Le Rouzic, O., Sendid, B., Viscogliosi, E., Le Pape, P., Arendrup, M. C., et al. (2018) · Indoor Air · doi:10.1111/ina.12436 · Cited by 41
Chen, Y., Li, Z., Han, X., Tian, S., Zhao, J., Chen, F., Su, X., Zhao, J., Zou, Z., Gong, Y., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01549-17 · Cited by 43
Self-citationAngeles, L. F., Singh, R. R., Vikesland, P. J., & Aga, D. S. (2021) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2021.125369 · Cited by 44
Azole‐resistant Aspergillus fumigatus as an emerging worldwide pathogen
Rivelli Zea, S. M., & Toyotome, T. (2022) · Microbiology and Immunology · doi:10.1111/1348-0421.12957 · Cited by 41
“They reported ARAf isolation rates of 50% (four of eight patients) and 75% (six of eight patients) from patients who had not previously received azole treatment.(9,10) Currently, there are two potential routes for the development of azole resistance in A.”
BackgroundInfluentialDiagnosis and management of aspergillosis in the Netherlands: a national survey
Lestrade, P. P. A., Meis, J. F., Arends, J. P., van der Beek, M. T., de Brauwer, E., van Dijk, K., de Greeff, S. C., Haas, P., Hodiamont, C. J., Kuijper, E. J., et al. (2016) · Mycoses · doi:10.1111/myc.12440 · Cited by 40
Self-citationLiposomal amphotericin B (AmBisome®) at beginning of its third decade of clinical use
Aversa, F., Busca, A., Candoni, A., Cesaro, S., Girmenia, C., Luppi, M., Nosari, A., Pagano, L., Romani, L. R., Rossi, G., et al. (2017) · Journal of Chemotherapy · doi:10.1080/1120009x.2017.1306183 · Cited by 42
Bassetti, M., Vena, A., Bouza, E., Peghin, M., Muñoz, P., Righi, E., Pea, F., Lackner, M., & Lass-Flörl, C. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.02.017 · Cited by 40
Mair, W. J., Thomas, G. J., Dodhia, K. N., Hills, A. L., Jayasena, K. W., Ellwood, S. R., Oliver, R. P., & López-Ruiz, F. J. (2020) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2020.103475 · Cited by 43
Aspergillus fumigatus Cross-Resistance between Clinical and Demethylase Inhibitor Azole Drugs
Garcia‐Rubio, R., González-Jiménez, I., Lucio, J. L., & Mellado, E. (2020) · Applied and Environmental Microbiology · doi:10.1128/aem.02539-20 · Cited by 41
Plant as an Alternative Source of Antifungals against Aspergillus Infections: A Review
Tan, L. F., Yap, V. L., Rajagopal, M. S., Wiart, C., Selvaraja, M., Leong, M. Y., & Tan, P. L. (2022) · Plants · doi:10.3390/plants11223009 · Cited by 49
“fumigatus has also been associated with a higher mortality rate [38,39].”
BackgroundFarmakiotis, D., & Kontoyiannis, D. P. (2015) · American Journal of Transplantation · doi:10.1111/ajt.13186 · Cited by 41
“Recently, the Clinical Laboratory Standards Institute and the European Committee for Antimicrobial Susceptibility Testing updated their susceptibility breakpoints forCandida spp. based on the integration of epidemiologic, molecular and clinical data (6–9).”
BackgroundInfluentialIn Vitro Biochemical Study of CYP51-Mediated Azole Resistance in Aspergillus fumigatus
Warrilow, A. G. S., Parker, J. E., Price, C. L., Nes, W. D., Kelly, S. L., & Kelly, D. E. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01806-15 · Cited by 38
“Clinical applications include assessing the likely impact of new emergent Af51A mutations, such as TR46/ Y121F/T289A (8), on the azole susceptibility of A. fumigatus strains that harbor the mutations.”
BackgroundANTIFUNGAL SUSCEPTIBILITY TESTING: CURRENT ROLE FROM THE CLINICAL LABORATORY PERSPECTIVE
Posteraro, B., Torelli, R., Carolis, E. D., Posteraro, P., & Sanguinetti, M. (2014) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2014.030 · Cited by 43
Pelaez, T., Monteiro, M. C., Garcia-Rubio, R., Bouza, E., Gomez-Lopez, A., & Mellado, E. (2015) · New Microbes and New Infections · doi:10.1016/j.nmni.2015.04.005 · Cited by 37
“Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.”
BackgroundInfluentialRivero-Menéndez, O., Soto-Debrán, J. C., Medina, N., Lucio, J. L., Mellado, E., & Alastruey‐Izquierdo, A. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00865-19 · Cited by 38
“mechanism of azole resistance described worldwide (TR34/L98H) (29–31) and one TR46/Y121F/T289A mechanism (32).”
BackgroundAhangarkani, F., Puts, Y., Nabili, M., Khodavaisy, S., Moazeni, M., Salehi, Z., Kargar, M. L., Badali, H., & Meis, J. F. G. M. (2020) · Mycoses · doi:10.1111/myc.13064 · Cited by 38
Viegas, C. S. B., Almeida, B., Caetano, L. A., Afanou, A. K., Straumfors, A., Veríssimo, C., Gonçalves, P., & Sabino, R. (2020) · International Journal of Environmental Health Research · doi:10.1080/09603123.2020.1810210 · Cited by 37
“…size and the flow rate used in this study were lower in comparison with other studies, where flow rate could reach 700 L of air for 20 min (van der Linden et al. 2013) and small aliquots from dust samples were used and frozen at −20 not ensuring 100% of viability of the isolates belonging to…”
ResultUnderstanding the environmental drivers of clinical azole resistance in Aspergillus species
Sen, P., Vijay, M., Singh, S., Hameed, S., & Vijayaraghavan, P. (2022) · Drug Target Insights · doi:10.33393/dti.2022.2476 · Cited by 40
The fungal UPR: A regulatory hub for virulence traits in the mold pathogen Aspergillus fumigatus
Krishnan, K., & Askew, D. S. (2014) · Virulence · doi:10.4161/viru.26571 · Cited by 35
MALDI-TOF Mass Spectrometry: Any Use for Aspergilli?
Sanguinetti, M., & Posteraro, B. (2014) · Mycopathologia · doi:10.1007/s11046-014-9757-1 · Cited by 35
“This considering that ever more patients are at risk of azoleresistant aspergillosis, due to the presence of resistant strains in the environment [41], the emergence and geographical migration of highly resistant strains [54] and the evolving of new mechanisms for azole resistance in this species [41].”
Arendrup, M. C., Hare, R. K., & Cuenca‐Estrella, M. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02336-15 · Cited by 35
Abdolrasouli, A., Petrou, M. A., Park, H. K., Rhodes, J. L., Rawson, T. M., Moore, L. S. P., Donaldson, H., Holmes, A. H., Fisher, M. C., & Armstrong-James, D. P. H. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02234 · Cited by 35
“Another cyp51A-mediated resistance alteration that leads to high-level voriconazole resistance, TR46/Y121F/T289A, has also been described in A. fumigatus (van der Linden et al., 2013).”
BackgroundGsaller, F., Hortschansky, P., Furukawa, T., Carr, P. D., Rash, B. M., Capilla, J., Müller, C., Bracher, F., Bowyer, P., Haas, H., et al. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1006106 · Cited by 35
Garcia‐Rubio, R., Escribano, P., Gómez, A., Guinea, J., & Mellado, E. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01626 · Cited by 35
“Strains with 46-bp promoter integration together with Y121F and T289A point mutations (Vermeulen et al., 2012; van der Linden et al., 2013; Pelaez et al., 2015), or only with 53-bp TR integration and without other cyp51A substitutions (Hodiamont et al., 2009; Le Pape et al., 2016), have been…”
BackgroundThe molecular mechanism of azole resistance in Aspergillus fumigatus: from bedside to bench and back
Wei, X., Zhang, Y., & Lü, L. (2015) · The Journal of Microbiology · doi:10.1007/s12275-015-5014-7 · Cited by 36
“The TR46/Y121F/T289A mutation contributes to high-level resistance to voriconazole (van der Linden et al., 2013; van Ingen et al., 2014).”
Epidemiology of antifungal susceptibility: Review of literature
Hadrich, I., & Ayadi, M. A. (2018) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2018.04.011 · Cited by 35
Roundtree, M. T., Juvvadi, P. R., Shwab, E. K., Cole, D., & Steinbach, W. J. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00735-20 · Cited by 33
Schauwvlieghe, A. F. A. D., de Jonge, N., van Dijk, K., Verweij, P. E., Brüggemann, R. J. M., Biemond, B. J., Bart, A., Borne, P. A. V. D., Verbon, A., van der Beek, M. T., et al. (2018) · Mycoses · doi:10.1111/myc.12788 · Cited by 31
Self-citationDetecting Azole-Antifungal Resistance in Aspergillus fumigatus by Pyrosequencing
van der Torre, M. H., Frazer, L. N., & Rautemaa‐Richardson, R. (2020) · Journal of Fungi · doi:10.3390/jof6010012 · Cited by 33
“The TR46/Y121F/T289A is a less widespread but emerging azole resistance mutation, which was first reported in the Netherlands in 2009 [60].”
BackgroundBataineh, M. T. A., Sutton, D. A., Fothergill, A. W., & Wiederhold, N. P. (2015) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.014 · Cited by 30
“covery of mechanisms of resistance associated with environmental exposure are concerning, because treatment options may be limited, and infections due to resistant isolates may be associated with a higher probability of treatment failure.(149,155,156)”
BackgroundYeoh, D. K., Moore, A. S., Kotecha, R. S., Bartlett, A. W., Ryan, A. L., Cann, M. P., McMullan, B. J., Thursky, K., Slavin, M. A., Blyth, C. C., et al. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.29275 · Cited by 30
Ross, B. S., Lofgren, L. A., Ashare, A., Stajich, J., & Cramer, R. A. (2021) · mBio · doi:10.1128/mbio.02153-21 · Cited by 31
Differences in epidemiology of candidaemia in the Nordic countries – what is to blame?
Hesstvedt, L., Arendrup, M. C., Poikonen, E., Klingpor, L., Friman, V., Nordøy, I., & The Swedish fungal Surveillance Group Collaborators (16) (2016) · Mycoses · doi:10.1111/myc.12535 · Cited by 30
Rai, M. K., Kon, K. V., Gade, A., Ingle, A. P., Nagaonkar, D., Paralikar, P., & da Silva, S. S. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803642-6.00006-x · Cited by 30
Bunskoek, P. E., Seyedmousavi, S., Gans, S. J. M., van Vierzen, P. B. J., Melchers, W. J. G., van Elk, C. E., Mouton, J. W., & Verweij, P. E. (2017) · Medical Mycology Case Reports · doi:10.1016/j.mmcr.2017.03.005 · Cited by 33
“…treatment of azole-resistant invasive aspergillosis in a bottlenose dolphin with high-dose posaconazole Paulien E. Bunskoeka, Seyedmojtaba Seyedmousavib,1, Steven J.M. Gansc, Peter B.J. van Vierzenc, Willem J.G. Melchersb,d, Cornelis E. van Elka, Johan W. Moutone, Paul E. Verweijb,d,⁎ a Veterinary…”
Self-citationIsavuconazonium sulfate: a triazole prodrug for invasive fungal infections
Murrell, D. E., Bossaer, J. B., Carico, R. “., Harirforoosh, S., & Cluck, D. B. (2016) · International Journal of Pharmacy Practice · doi:10.1111/ijpp.12302 · Cited by 33
“While resistance in Candida species has been an ongoing therapeutic problem, resistance in Aspergillus species has emerged in recent years and is of significant concern therapeutically.([61,62]) Aspergillus species have different targets and thus different mechanisms of resistance compared to Candida species.”
BackgroundSchauwvlieghe, A. F. A. D., Vonk, A. G., Buddingh, E. P., Hoek, R. A. S., Dalm, V. A. S. H., Klaassen, C. H. W., & Rijnders, B. J. A. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx262 · Cited by 28
Self-citationFuture Research Priorities in Fungal Resistance
McCarthy, M. W., Denning, D. W., & Walsh, T. J. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix103 · Cited by 32
“Although more than 15 Cyp51A RAMs have been described, only 4 appear in the current iteration of the assay, and these mutations tend to originate from the environment, not from prolonged azole treatment [19, 20].”
BackgroundDiversity and origins of Indian multi‐triazole resistant strains of Aspergillus fumigatus
Chang, H., Ashu, E. E., Sharma, C., Kathuria, S., Chowdhary, A., & Xu, J. (2016) · Mycoses · doi:10.1111/myc.12494 · Cited by 28
Fungal Infections Complicating Lung Transplantation
Clark, N. M., WEIGT, S. S., Fishbein, M. C., Kubak, B., Belperio, J. A., & Lynch, J. P. (2018) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0037-1617443 · Cited by 33
Recent developments in Aspergillus fumigatus research: diversity, drugs, and disease
Kordana, N. E., Johnson, A., Quinn, K., Obar, J. J., & Cramer, R. A. (2025) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00011-23 · Cited by 29
Chitasombat, M. N., & Kontoyiannis, D. P. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1057500 · Cited by 27
“to triazoles is also a concerning issue in some geographic areas [2].”
BackgroundMello, E., Posteraro, B., Vella, A., Carolis, E. D., Torelli, R., D’Inzeo, T., Verweij, P. E., & Sanguinetti, M. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00168-17 · Cited by 29
Self-citationTalbot, J. J., Frisvad, J. C., Meis, J. F. G. M., Hagen, F., Verweij, P. E., Hibbs, D. E., Lai, F., Groundwater, P. W., Samson, R. A., Kidd, S. E., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00632-19 · Cited by 27
Self-citationEmergence of Triazole Resistance in Aspergillus spp. in Latin America
Macedo, D., Leonardelli, F., Gamarra, S. P., & García‐Effrón, G. (2021) · Current Fungal Infection Reports · doi:10.1007/s12281-021-00418-6 · Cited by 27
Mavridou, E., Meletiadis, J., Rijs, A., Mouton, J. W., & Verweij, P. E. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04469-14 · Cited by 29
“Very recently, a new environmental azole resistance mechanism consisting of TR46/Y121F/T289A was reported to be associated with voriconazole treatment failure in patients with invasive aspergillosis (11, 12).”
BackgroundSelf-citationJuvvadi, P. R., Moseley, M. A., Hughes, C. J., Soderblom, E. J., Lennon, S., Perkins, S. R., Thompson, J. W., Geromanos, S. J., Wildgoose, J. L., Richardson, K., et al. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.7b00499 · Cited by 26
Valdes, I. D., van den Berg, J., Haagsman, A. N., Escobar, N., Meis, J. F. G. M., Hagen, F., Haas, P. J. A., Houbraken, J. A. M. P., Wösten, H. A. B., & de Cock, H. (2018) · BMC Microbiology · doi:10.1186/s12866-018-1244-2 · Cited by 28
Self-citationEmergence of Azole-Resistant Aspergillus fumigatus from Immunocompromised Hosts in India
Dabas, Y., Xess, I., Bakshi, S., Mahapatra, M., & Seth, R. K. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02264-17 · Cited by 27
Diagnostics and Susceptibility Testing in Aspergillus
Bernal-Martínez, L., Alastruey-Izquierdo, A., & Cuenca-Estrella, M. (2016) · Future Microbiology · doi:10.2217/fmb.15.140 · Cited by 25
High-Level Pan-Azole-Resistant Aspergillosis
van Ingen, J., van der Lee, H. A. L., Rijs, A. J. M. M., Snelders, E., Melchers, W. J. G., & Verweij, P. E. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.00502-15 · Cited by 25
Self-citationEmergence of TR46/Y121F/T289A in an Aspergillus fumigatus Isolate from a Chinese Patient
Chen, Y., Wang, H., Lu, Z., Li, P., Zhang, Q., Jia, T., Zhao, J., Tian, S., Han, X., Chen, F., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00887-15 · Cited by 25
Posaconazole Prophylaxis in Experimental Azole-Resistant Invasive Pulmonary Aspergillosis
Seyedmousavi, S., Mouton, J. W., Melchers, W. J. G., & Verweij, P. E. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03850-14 · Cited by 28
Self-citationChong, G. M., Broekman, F., Polinder, S., Doorduijn, J. K., Lugtenburg, P. J., Verbon, A., Cornelissen, J. J., & Rijnders, B. J. A. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2015.02.023 · Cited by 27
Self-citationWilliams, C. C., Gregory, J., & Usher, J. (2024) · Microbiology · doi:10.1099/mic.0.001512 · Cited by 26
Öz, Y., Özdemir, H. G., Gökbolat, E., Kiraz, N., İlkit, M., & Seyedmousavi, S. (2015) · Mycopathologia · doi:10.1007/s11046-015-9969-z · Cited by 24
Ahmad, S., Khan, Z., Hagen, F., & Meis, J. F. G. M. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.00408-14 · Cited by 23
“fumigatus isolates containing a tandem repeat in the promoter region but lacking the L98H mutation would indicate the presence of Y121F/T289A in the cyp51A gene, which could be subsequently confirmed by other methods (20).”
Macedo, D., Leonardelli, F., Dudiuk, C., Theill, L., Cabeza, M. S., Gamarra, S. P., & García‐Effrón, G. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00224-18 · Cited by 26
Isla, G., Leonardelli, F., Tiraboschi, I. N., Refojo, N., Hevia, A., Vivot, W., Szusz, W., Córdoba, S. B., & García‐Effrón, G. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00872-18 · Cited by 23
New case of azole-resistant Aspergillus fumigatus due to TR46/Y121F/T289A mutation in Belgium
Montesinos, I., Dodémont, M., Lagrou, K., Jacobs, F., Etienne, I., & Denis, O. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku289 · Cited by 24
González-Jiménez, I., Lucio, J., Menéndez-Fraga, M. D., Mellado, E., & Peláez, T. (2021) · Journal of Fungi · doi:10.3390/jof7010022 · Cited by 25
“IPAand other forms of aspergillosis are currently being treated with a class of antifungal compounds named azoles [1,4].”
BackgroundInfluentialRocchi, S., Sewell, T. R., Valot, B., Godeau, C., Laboissière, A., Millon, L., & Fisher, M. C. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.729476 · Cited by 23
“For both clinical and environmental samples, A. fumigatus were first isolated on malt agar media supplemented by itraconazole (2 mg L−1) or voriconazole (1 mg L−1) (van der Linden et al., 2013; Bader et al., 2015) at 37°C for clinical ones and 48°C for environmental ones.”
BackgroundTashiro, M., Nakano, Y., Shirahige, T., Kakiuchi, S., Fujita, A., Tanaka, T., Takazono, T., & Izumikawa, K. (2025) · Journal of Fungi · doi:10.3390/jof11020096 · Cited by 21
“Mortality rates associated with invasive aspergillosis caused by azole-resistant A. fumigatus can increase significantly—some studies report rates exceeding 50% when first-line azole therapy fails—emphasizing the severity of this emerging threat [8,28,29].”
Azole-Resistant Aspergillus fumigatus: Epidemiology, Diagnosis, and Treatment Considerations
Zubovskaia, A. (2025) · Journal of Fungi · doi:10.3390/jof11100731 · Cited by 23
Gonçalves, S. S. (2017) · Journal of Fungi · doi:10.3390/jof3010005 · Cited by 22
“fumigatus strains has been reported in patients with IA who were not previously exposed to azole treatments and who could be considered azole-naive [4,41,59,60].”
BackgroundWarris, A. (2015) · Journal of Infection · doi:10.1016/j.jinf.2015.04.023 · Cited by 21
Siopi, M., Rivero-Menéndez, O., Gkotsis, G., Panara, A., Τhomaidis, Ν. S., Alastruey‐Izquierdo, A., Pournaras, S., & Meletiadis, J. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa316 · Cited by 21
Souza, A. C. O., Ge, W., Wiederhold, N. P., Rybak, J. M., Fortwendel, J. R., & Rogers, P. D. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.05188-22 · Cited by 20
Voriconazole-refractory invasive aspergillosis
Park, S. Y., Yoon, J.-A., & Kim, S. (2017) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2017.109 · Cited by 21
Reed, K., Macgregor, S. K., Stidworthy, M. F., Denk, D., & Guthrie, A. L. (2020) · Journal of Zoo and Wildlife Medicine · doi:10.1638/2019-0160 · Cited by 20
“Isolation of drug-resistant AF strains from environmental samples have suggested a route of selection for azole resistance, which has been hypothesized to be environmental fungicide-driven, because of the prevalence of resistant infections in patients with no history of undergoing treatment with azoles.(25) Azoles are…”
BackgroundZhou, D., Wang, R., Li, X., Peng, B., Yang, G., Zhang, K., Zhang, Y., & Xu, J. (2021) · Microbial Ecology · doi:10.1007/s00248-021-01804-w · Cited by 20
“The most widespread one was TR34/L98H, consistent with the multiple origins of this mutation.”
BackgroundInfluentialDoughty, K. J., Sierotzki, H., Semar, M., & Goertz, A. (2021) · Microorganisms · doi:10.3390/microorganisms9122439 · Cited by 19
“widespread “environmental” mutant, TR46/Y121F/T289A, was first recovered from a Dutch patient in 2009 [9,10,41,42] and later found in a sample from a US patient taken in 2008 [43].”
BackgroundAzole Combinations and Multi-Targeting Drugs That Synergistically Inhibit Candidozyma auris
Toepfer, S., Keniya, M. V., Lackner, M., & Monk, B. C. (2024) · Journal of Fungi · doi:10.3390/jof10100698 · Cited by 23
“As has been documented for A. fumigatus CYP51A mutations that confer resistance to VRC in azole naïve patients [207–209], this problem is already limiting therapeutic options.”
BackgroundAzole Resistance-Associated Regulatory Motifs within the Promoter of cyp51A in Aspergillus fumigatus
Kühbacher, A., Peiffer, M., Hortschansky, P., Merschak, P., Bromley, M., Haas, H., Brakhage, A. A., & Gsaller, F. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01209-22 · Cited by 19
“the aforementioned TR34 and TR46 as well as TR53 and TR120 (7, 8, 11, 12).”
Novel Treatment Approach for Aspergilloses by Targeting Germination
Verburg, K., van Neer, J., Duca, M., & de Cock, H. (2022) · Journal of Fungi · doi:10.3390/jof8080758 · Cited by 21
“These findings are in line with earlier findings that related azole-resistant strains to the isolates that caused IPA could be found in air samples in the surrounding environment [148] and which was confirmed by population genomics analysis [145].”
BackgroundResultInfluential
Metadata
- Authors
- van der Linden, J. W. M., Camps, S. M. T., Kampinga, G. A., Arends, J. P. A., Debets-Ossenkopp, Y. J., Haas, P. J. A., Rijnders, B. J. A., Kuijper, E. J., van Tiel, F. H., Varga, J., Karawajczyk, A., Zoll, J., Melchers, W. J. G., & Verweij, P. E.
- Affiliations
- Radboud University Nijmegen (NL)
- University Medical Center Groningen (NL)
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- University Medical Center Utrecht (NL)
- Erasmus MC (NL)
- Leiden University Medical Center (NL)
- University of Szeged (HU)
- Radboud University Medical Center (NL)
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-05-10
- Volume
- 57
- Issue
- 4
- Pages
- 513-520
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2142912010
- Cited by
- 342
- References
- 31
- Citations by year
- 2026: 5 · 2025: 17 · 2024: 15 · 2023: 21 · 2022: 13 · 2021: 28 · 2020: 25 · 2019: 21 · 2018: 32 · 2017: 38 · 2016: 38 · 2015: 40 · 2014: 34 · 2013: 13
- FWCI
- 30.27
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- Pfizer
- Gilead Sciences
- ZonMw
- Astellas Pharma
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- Aspergillus fumigatus, voriconazole resistance, azole resistance, invasive aspergillosis, cyp51A mutations, azole fungicides, environmental isolates, treatment failure, antifungal resistance surveillance
- MeSH terms
- Aged, Air Microbiology, Antifungal Agents, Aspergillosis, Aspergillus fumigatus, Child, Female, Genes, Fungal, Genotype, Hospitals, Humans, Male, Middle Aged, Netherlands, Pyrimidines, Surveys and Questionnaires, Residence Characteristics, Selection, Genetic, Triazoles, Mycological Typing Techniques, Treatment Failure, Sequence Analysis, DNA, Drug Resistance, Fungal, Young Adult, Molecular Typing, Voriconazole
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.